(Q34240696)

31 July 2017

0 references

Randomized, placebo-controlled trials of antidepressants for acute major depression: thirty-year meta-analytic review (English)

1 reference

31 July 2017

0 references

1 reference

Juan Undurraga

1

0 references

Ross J. Baldessarini

series ordinal

2

object named as

Ross J Baldessarini

1 reference

31 July 2017

language of work or name

English

0 references

publication date

14 December 2011

1 reference

31 July 2017

published in

Neuropsychopharmacology

1 reference

31 July 2017

volume

37

1 reference

31 July 2017

issue

4

1 reference

31 July 2017

page(s)

851-864

1 reference

https://scigraph.springernature.com/pub.10.1038/npp.2011.306

31 July 2017

exact match

0 references

cites work

Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Multisite international collaborative clinical trials in mania

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Efficacy of antimanic treatments: meta-analysis of randomized, controlled trials

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Efficacy and effectiveness of antidepressants: current status of research

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Illness risk following rapid versus gradual discontinuation of antidepressants

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Pharmacotherapy of major depressive disorder in adolescents.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Last-observation-carried-forward imputation method in clinical efficacy trials: review of 352 antidepressant studies

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Why antidepressants are not antidepressants: STEP-BD, STAR*D, and the return of neurotic depression

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Efficacy of antidepressants in juvenile depression: meta-analysis

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Effectiveness of antidepressants: an evidence myth constructed from a thousand randomized trials?

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug Administration

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Selective Publication of Antidepressant Trials and Its Influence on Apparent Efficacy

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Metareview on short-term effectiveness and safety of antidepressants for depression: an evidence-based approach to inform clinical practice.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Comparative efficacy and safety of a once-daily dosage of hypericum extract STW3-VI and citalopram in patients with moderate depression: a double-blind, randomised, multicentre, placebo-controlled study

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

A rating scale for depression

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Placebo response in studies of major depression: variable, substantial, and growing

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Effect of Hypericum perforatum (St John's wort) in major depressive disorder: a randomized controlled trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Meta-analytical studies on new antidepressants.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Comparison of pramipexole, fluoxetine, and placebo in patients with major depression

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Multicenter, placebo-controlled, fixed-dose study of citalopram in moderate-to-severe depression

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Sexual dysfunction associated with the treatment of depression: a placebo-controlled comparison of bupropion sustained release and sertraline treatment

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Hypericum extract versus imipramine or placebo in patients with moderate depression: randomised multicentre study of treatment for eight weeks

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

A double-blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

A double-blind, placebo-controlled study comparing the effects of sertraline versus amitriptyline in the treatment of major depression

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Efficacy of venlafaxine in depressive illness in general practice

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Fluvoxamine maleate in the treatment of depression: a single-center, double-blind, placebo-controlled comparison with imipramine in outpatients

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Evidence based medicine: what it is and what it isn't

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

A double-blind, placebo-controlled comparison of sertraline and dothiepin in the treatment of major depression in general practice.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Regression towards the mean

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Randomised controlled trial comparing problem solving treatment with amitriptyline and placebo for major depression in primary care

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

A double-blind, placebo-controlled study comparing mianserin and amitriptyline in moderately depressed outpatients

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

A double-blind placebo-controlled study of fluvoxamine and imipramine in out-patients with primary depression

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

A double-blind evaluation of zimelidine in comparison to placebo and amitmptyline in patients with major depressive disorder

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

A comparison of fluoxetine, imipramine, and placebo in patients with major depressive disorder

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Alprazolam, diazepam, imipramine, and placebo in outpatients with major depression.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Double-blind placebo-controlled trial of amitriptyline among depressed patients in general practice

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Comparative efficacy of alprazolam, imipramine, and placebo administered once a day in treating depressed patients

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Alprazolam, amitriptyline, doxepin, and placebo in the treatment of depression

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Phenelzine and imipramine in mood reactive depressives. Further delineation of the syndrome of atypical depression.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Tyrosine for depression: a double-blind trial

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

A fixed-dose (300 mg) efficacy study of bupropion and placebo in depressed outpatients

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Venlafaxine in depressed outpatients

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

A controlled study of mianserin in moderately to severely depressed outpatients

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

A 6-week, double-blind trial of paroxetine, imipramine, and placebo in depressed outpatients.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

A double-blind, placebo-controlled study of paroxetine in depressed outpatients.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Paroxetine versus placebo: a double-blind comparison in depressed patients

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

A double-blind comparison of paroxetine, imipramine and placebo in depressed outpatients

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

A New Depression Scale Designed to be Sensitive to Change

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression

6 July 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2011.306

A comparison of moclobemide, amitriptyline and placebo in depression: a Canadian multicentre study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2011.306

Hypericum extract LI 160 and fluoxetine in mild to moderate depression: a randomized, placebo-controlled multi-center study in outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2011.306

Transdermal selegiline in major depression: a double-blind, placebo-controlled, parallel-group study in outpatients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2011.306

Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2011.306

Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2011.306

A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2011.306

Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2011.306

A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2011.306

A Double-Blind Study of Paroxetine, Fluoxetine, and Placebo in Outpatients with Major Depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2011.306

Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2011.306

Double-blind, placebo-controlled comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2011.306

Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2011.306

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2011.306

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2011.306

Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2011.306

Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2011.306

A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2011.306

Placebo-controlled inpatient comparison of venlafaxine and fluoxetine for the treatment of major depression with melancholic features

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2011.306

Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2011.306

Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2011.306

Factors modifying drug and placebo responses in randomized trials for bipolar mania.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2011.306

A placebo-controlled study evaluating the efficacy and safety of flexible-dose desvenlafaxine treatment in outpatients with major depressive disorder

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Selegiline transdermal system for the treatment of major depressive disorder: an 8-week, double-blind, placebo-controlled, flexible-dose titration trial.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Effectiveness of low doses of paroxetine controlled release in the treatment of major depressive disorder.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Duloxetine, 60 mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Double-blind comparison of citalopram and placebo in depressed outpatients with melancholia.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Reboxetine versus fluoxetine: an overview of efficacy and tolerability.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

A comparison of venlafaxine, trazodone, and placebo in major depression.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

A placebo-controlled inpatient comparison of fluvoxamine maleate and imipramine in major depression.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3280655

Once-Daily Venlafaxine Extended Release (XR) and Venlafaxine Immediate Release (IR) in Outpatients with Major Depression

28 October 2018

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2011.306

Comparison of Alprazolam, Imipramine, and Placebo in the Treatment of Depression

21 January 2018

1 reference

12 December 2020

A double-blind comparison of gepirone extended release, imipramine, and placebo in the treatment of outpatient major depression

1 reference

12 December 2020

Treatment of depressive outpatients with lorazepam, alprazolam, amytriptyline and placebo

1 reference

12 December 2020

The efficacy and safety of paroxetine compared with placebo in outpatients with major depression

1 reference

12 December 2020

A study comparing paroxetine placebo and imipramine in depressed patients

1 reference

12 December 2020

Double-blind study of mirtazapine and placebo in hospitalized patients with major depression

1 reference

12 December 2020

The use of venlafaxine in the treatment of major depression and major depression associated with anxiety: a dose-response study. Venlafaxine Investigator Study Group

1 reference

12 December 2020

A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression

1 reference

12 December 2020

Bupropion in depression: a tri-center placebo-controlled study

1 reference

12 December 2020

Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder

1 reference

12 December 2020

A multicenter evaluation of the efficacy and safety of 150 and 300 mg/d sustained-release bupropion tablets versus placebo in depressed outpatients

1 reference

12 December 2020

Paroxetine in major depression: a double-blind trial with imipramine and placebo

1 reference

12 December 2020

A double-blind comparison of fluoxetine, imipramine and placebo in outpatients with major depression

1 reference

12 December 2020

Low-dose fluoxetine therapy for depression

1 reference

12 December 2020

Mirtazapine vs. amitriptyline vs. placebo in the treatment of major depressive disorder

1 reference

12 December 2020

A double-blind comparison of paroxetine and placebo in the treatment of depressed patients in a psychiatric outpatient clinic

1 reference

12 December 2020

Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group

1 reference

12 December 2020

Responders to antidepressant drug treatment: a study comparing nefazodone, imipramine, and placebo in patients with major depression

1 reference

12 December 2020

Once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Venlafaxine XR 208 Study Group

1 reference

12 December 2020

Tranylcypromine vs nortriptyline vs placebo in depressed outpatients: a controlled trial

1 reference

12 December 2020

Comparison of venlafaxine and imipramine in the acute treatment of major depression in outpatients

1 reference

12 December 2020

A double-blind placebo-controlled study of Org 3770 in depressed outpatients

1 reference

12 December 2020

A multicentre comparative trial of moclobemide, imipramine and placebo in major depressive disorder. UK Moclobemide Study Group

1 reference

12 December 2020

Fixed-dose fluoxetine therapy for depression

1 reference

12 December 2020

Efficacy and tolerability of once-daily venlafaxine extended release (XR) in outpatients with major depression. The Venlafaxine XR 209 Study Group

1 reference

12 December 2020

A double-blind comparison of fluvoxamine, desipramine and placebo in outpatients with depression

1 reference

12 December 2020

Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression: a randomized double-blind trial in a Brazilian sample

1 reference

12 December 2020

A double-blind comparison of nefazodone, imipramine, and placebo in major depression

1 reference

12 December 2020

Moclobemide and clomipramine in reactive depression. A placebo-controlled randomized clinical trial

1 reference

12 December 2020

Effectiveness of venlafaxine in patients hospitalized for major depression and melancholia

1 reference

12 December 2020

Nefazodone and imipramine in major depression: a placebo-controlled trial

1 reference

12 December 2020

A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression

1 reference

12 December 2020

A double-blind comparison of Org 3770, amitriptyline, and placebo in major depression

1 reference

12 December 2020

A double-blind comparison of tianeptine, imipramine and placebo in the treatment of major depressive episodes

1 reference

12 December 2020

Clinical efficacy of reboxetine: a comparative study with desipramine, with methodological considerations

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2011.306

7 January 2021

inferred from DOI database lookup

Treatment decisions for type 2 diabetes

1 reference

https://api.crossref.org/works/10.1038%2FNPP.2011.306

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1038/NPP.2011.306

1 reference

Dimensions Publication ID

31 July 2017

0 references

1 reference

31 July 2017

1 reference